Stryker CORP 8-K filings

Stryker Corporation announced robust second quarter 2026 financial results, with net sales up 9.4% and EPS soaring 44.1%, signaling a strong recovery post-cyber incident.

Stryker Corporation has recast its historical financial statements to reflect a new organizational structure, creating an 'Ortho Tech' business segment.

Stryker Corporation announces the retirement of its Vice President and Chief Accounting Officer, William E. Berry, Jr., effective September 1, 2026, with Emily Baculik appointed as his successor.

Stryker Corporation shareholders re-elected all ten directors, ratified the appointment of Ernst & Young LLP, and approved executive compensation at the 2026 Annual Meeting.

Stryker reported a 2.6% increase in Q1 2026 net sales to $6.0 billion, maintaining full-year guidance despite a recent cybersecurity incident.

Stryker Corporation filed an amendment to its Form 8-K, providing further details on a material cybersecurity incident that impacted its operations in Q1 2026.

Stryker Corporation provides an update on its cybersecurity incident, confirming containment and no identified malicious activity directed at customer or partner systems.

Stryker Corporation disclosed a global disruption to its Microsoft environment due to a cybersecurity incident, impacting order processing, manufacturing, and shipping.

Stryker reports robust double-digit sales and adjusted EPS growth for Q4 and full-year 2025, exceeding $25 billion in revenue and providing an optimistic 2026 outlook.

Stryker Corporation announced key leadership changes, promoting Spencer Stiles to President and COO and Dylan Crotty to Group President, Orthopaedics, effective January 1, 2026.

Stryker announced robust third-quarter 2025 operating results, with significant sales growth and double-digit adjusted EPS increase, leading to an upward revision of its full-year guidance.

Stryker Corporation announced impressive second quarter 2025 operating results, showcasing double-digit sales and adjusted earnings per share growth, which led to an upward revision of its full-year 2025 financial outlook.

Stryker Corporation's shareholders approved the amended and restated 2011 Long-Term Incentive Plan, the 2011 Performance Incentive Award Plan, and the 2008 Employee Stock Purchase Plan, and elected all ten director nominees at the Annual Meeting held on May 8, 2025.

Stryker Corporation announces a robust first quarter in 2025, marked by double-digit organic sales growth and an increase in adjusted operating margins, leading to an upward revision of the full-year organic net sales growth forecast.

Stryker Corporation secured a new $3 billion revolving credit agreement maturing in 2030, replacing its previous facility and providing financial flexibility for future acquisitions.

Stryker Corporation finalized its acquisition of Inari Medical for approximately $4.94 billion in cash on February 19, 2025.

Allan Golston will retire from Stryker's Board of Directors effective at the company's annual meeting of shareholders expected on May 8, 2025.

Stryker Corporation has successfully completed a public offering of $3 billion in notes with varying maturities and interest rates to fund the acquisition of Inari Medical, Inc. and for general corporate purposes.

Stryker Corporation announces the retirement of CFO Glenn S. Boehnlein and the promotion of Preston W. Wells to the role, effective April 1, 2025.

Stryker announced robust 2024 financial results, including double-digit organic sales growth, and provided an optimistic outlook for 2025.

Stryker Corporation has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, totaling approximately $4.9 billion, marking Stryker's entry into the high-growth peripheral vascular segment.

Stryker Corporation announced robust third-quarter 2024 results, with significant sales growth and increased profitability, leading to an improved full-year outlook.

Stryker Corporation successfully priced and closed a $3 billion debt offering, issuing both Euro and USD denominated notes to refinance existing debt and for general corporate purposes.

Stryker Corporation announced robust second-quarter 2024 results, with net sales increasing by 8.5% and organic sales up 9.0%, leading to an improved full-year outlook.

Stryker Corporation held its annual shareholder meeting on May 9, 2024, where all ten director nominees were elected, the appointment of Ernst & Young LLP as the independent auditor was ratified, executive compensation was approved, and a shareholder proposal on political spending transparency was not approved.

Stryker's first quarter of 2024 saw a 10% increase in organic sales growth, leading to a significant rise in earnings per share.

Stryker Corporation announced robust fourth quarter and full-year 2023 results, highlighted by double-digit sales growth and a positive outlook for 2024.